KYMR
Kymera Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Kymera Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Annual filing, covered
10-K parsed · Feb 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
+0.07%
vs ±18.2% implied · ×0.00
shaded = implied · ▲▼ = realized
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; of Kymera Therapeutics, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; of Kymera Therapeutics, Inc.'s 6 closest co-movers, none share that code.
Linked news
Tall tick = annual report · Source: EDGAR
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $1.4B | 12.63% | +5.55% |
| Baker Bros. | $992.7M | 8.86% | 0.00% |
| venBio Select Advisor | $857.1M | 7.65% | 0.00% |
| T. Rowe Price | $815.6M | 7.28% | +17.36% |
| T. Rowe Price | $717.5M | 6.40% | +14.50% |
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $1.4B | 12.63% | +5.55% |
| Baker Bros. | $992.7M | 8.86% | 0.00% |
| venBio Select Advisor | $857.1M | 7.65% | 0.00% |
| T. Rowe Price | $815.6M | 7.28% | +17.36% |
| T. Rowe Price | $717.5M | 6.40% | +14.50% |
—
Bull3
Bear2
Kymera Therapeutics, Inc.
127.92
+0.83 · +0.65%
Expected move
Inputs8Q avg ±2.2%·×18.06·rich
straddle ±43.2%
spot 127.09exp Jan 15ATM strike 125ATM straddle 64.65IV 149%